Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxin Dawaimixike Migao for chronic stable angina pectoris
ChiCTR2000029225Phase 4Not yet recruiting
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of yangxin dawaimixike migao in angina pectoris (2 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoints: Number of angina episodes per week, Duration of angina attacks and 2 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
yangxin dawaimixike migao
03
Conditions
angina pectoris
Beyond the preview
Go deeper on ChiCTR2000029225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029225.